Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436

The Vasopressin V1bReceptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders

(2012) Guy Griebel et al.   JOURNAL OF CLINICAL PSYCHIATRY

Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

(2012) Guy Griebel et al.   NATURE REVIEWS DRUG DISCOVERY

A review of Atypical depression in relation to the course of depression and changes in HPA axis organization

(2012) Veronica O’Keane et al.   PSYCHONEUROENDOCRINOLOGY

Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety

(2011) Jayne E Bailey et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder

(2010) Vladimir Coric et al.   DEPRESSION AND ANXIETY

The vasopressin Avpr1b receptor: Molecular and pharmacological studies

(2010) JA Roper et al.   STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS

A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH1Antagonist) in the Treatment of Major Depression

(2008) Brendon Binneman et al.   AMERICAN JOURNAL OF PSYCHIATRY

Elevated plasma arginine vasopressin levels in veterans with posttraumatic stress disorder

(2007) C.S. de Kloet et al.   JOURNAL OF PSYCHIATRIC RESEARCH